Krepp Sarah sold $17K of LQDA

Krepp Sarah (Chief Human Resource Officer) sold 276 shares of Liquidia Corp (LQDA) at $60.87 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Krepp Sarah
Published Jun 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 designation and small dollar amount reduce expected market impact.

03

What to watch

The disclosure does not indicate intent beyond the pre-arranged plan, and the sale size ($16.8k) is small relative to typical institutional trading flows.

Relevance 2/10Novelty 3/10Timing: Filed 2026-06-03, disclosing a 2026-06-01 insider sale.

Background

The article is an SEC Form 4 insider transaction filing for Liquidia Corp, reported by an officer (Chief Human Resource Officer).

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia insider Krepp Sarah, Chief Human Resource Officer, sold 276 shares at $60.87 on 2026-06-01 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 reports an open-market sale with a pre-arranged 10b5-1 plan, providing no new company fundamentals or guidance in the text.

Market effects

No sector-level implications; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may interpret insider selling as a signal of reduced confidence, especially if multiple insiders sell around the same period.

Key entities

  • Liquidia Corp

    US-listed company subject of the Form 4 insider transaction disclosure.

  • Krepp Sarah

    Chief Human Resource Officer who sold 276 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.